The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

Macular degeneration is a condition that affects the retina, which is neural tissue that lines the back of the eye, like wallpaper in a room. There is an important area ...

In response to the TGA's approval of a new drug to treat macular degeneration, UNSW researcher Dr Lisa Nivison-Smith provides context about the ...

The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release. The decision was ...

(aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration ... human antibodies and new classes of bispecific antibodies.

6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic ... approval for wet (neovascular) age-related macular degeneration. The ranibizumab injection (Lucentis ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...